Literature DB >> 7719943

Asymmetric signaling requirements for thymocyte commitment to the CD4+ versus CD8+ T cell lineages: a new perspective on thymic commitment and selection.

H Suzuki1, J A Punt, L G Granger, A Singer.   

Abstract

Differentiation of immature CD4+ CD8+ thymocytes into mature CD4+ CD8- and CD4-CD8+ T cells requires that synthesis of one or the other coreceptor molecule be terminated, a process referred to as lineage commitment. The present study has utilized a novel coreceptor reexpression assay to identify lineage commitment in immature thymocytes and has found that the MHC recognition requirements for CD4 commitment and CD8 commitment fundamentally differ from one another. Remarkably, we found that thymocyte commitment to the CD8+ lineage requires MHC class I-dependent instructional signals, whereas thymocyte commitment to the CD4+ lineage is MHC independent and may occur by default. In addition, an unanticipated relationship between lineage commitment and surface phenotype has been identified. These results are incompatible with current concepts and require a new perspective on lineage commitment and positive selection, which we refer to as asymmetric commitment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719943     DOI: 10.1016/1074-7613(95)90149-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  44 in total

1.  Precise arrangement of factor-binding sites is required for murine CD4 promoter function.

Authors:  S Sarafova; G Siu
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

Review 2.  Ligand-dependent regulation of T cell development and activation.

Authors:  Ronald N Germain
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice.

Authors:  Alfred Singer; Stanley Adoro; Jung-Hyun Park
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

4.  CD8 coreceptor extinction in signaled CD4(+)CD8(+) thymocytes: coordinate roles for both transcriptional and posttranscriptional regulatory mechanisms in developing thymocytes.

Authors:  R Cibotti; A Bhandoola; T I Guinter; S O Sharrow; A Singer
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

5.  Treatment with anti-LFA-1 alpha monoclonal antibody selectively interferes with the maturation of CD4- 8+ thymocytes.

Authors:  C Revilla; A L González; C Conde; M López-Hoyos; J Merino
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

6.  Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes.

Authors:  Julie L Mitchell; Amara Seng; Thomas M Yankee
Journal:  Immunology       Date:  2016-09-20       Impact factor: 7.397

7.  Two distinct pathways of positive selection for thymocytes.

Authors:  K Akashi; M Kondo; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

8.  Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells.

Authors:  Jung-Hyun Park; Stanley Adoro; Terry Guinter; Batu Erman; Amala S Alag; Marta Catalfamo; Motoko Y Kimura; Yongzhi Cui; Philip J Lucas; Ronald E Gress; Masato Kubo; Lothar Hennighausen; Lionel Feigenbaum; Alfred Singer
Journal:  Nat Immunol       Date:  2010-01-31       Impact factor: 25.606

9.  Differential role of the transcription factor NF-kappaB in selection and survival of CD4+ and CD8+ thymocytes.

Authors:  Eijiro Jimi; Ian Strickland; Reinhard E Voll; Meixiao Long; Sankar Ghosh
Journal:  Immunity       Date:  2008-10-17       Impact factor: 31.745

10.  The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus.

Authors:  Monica Zamisch; Linhua Tian; Roland Grenningloh; Yumei Xiong; Kathryn F Wildt; Marc Ehlers; I-Cheng Ho; Rémy Bosselut
Journal:  J Exp Med       Date:  2009-11-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.